Efficacy and safety of deep hyperthermia combined with tislelizumab and chemotherapy in the treatment of advanced squamous non-small-cell lung cancer: a single-center retrospective study - Top-Institutions - MDSpire

Efficacy and safety of deep hyperthermia combined with tislelizumab and chemotherapy in the treatment of advanced squamous non-small-cell lung cancer: a single-center retrospective study

  • By

  • LiYing Guo

  • Jinshuo Wang

  • Dongjie Du

  • April 30, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Thoracic Oncology
    • Immunotherapy
    • Hyperthermia Therapy

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Thoracic Oncology
    • Immunotherapy
    • Translational Cancer Research

  • #3

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Thoracic Oncology
    • Immunotherapy
    • Clinical Trials

  • #4

    National Cancer Center Hospital
    National Cancer Center Hospital

    Tokyo, Tokyo

    Key Differentiators

    • Thoracic Oncology
    • Immunotherapy
    • Hyperthermia Therapy

  • #5

    Fudan University Shanghai Cancer Center
    Fudan University Shanghai Cancer Center

    Shanghai, Shanghai

    Key Differentiators

    • Thoracic Oncology
    • Immunotherapy
    • Hyperthermia Therapy

Original Source(s)

Efficacy and safety of deep hyperthermia combined with tislelizumab and chemotherapy in the treatment of advanced squamous non-small-cell lung cancer: a single-center retrospective study

  • by LiYing Guo, Jinshuo Wang, Dongjie Du

  • April 30, 2026

Related Content

Zapnometinib treatment and influenza A virus infection modulate the HLA class I ligandome in human lung adenocarcinoma cells

Imaging features of lung cancer with cystic airspaces: clinical utility, challenges, and perspectives

Editorial: Epigenetic modulation in cancer